Protagonist Therapeutics (PTGX) total liabilities

Total liabilities · fiscal 2025
$53.48M

Protagonist Therapeutics (PTGX) had total liabilities of $53.48M at the end of fiscal 2025 (December 31, 2025). That is 23.0% lower than the $69.43M of fiscal 2024. Figures as of 19 Nov 2026, 11:21 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$53.48M
Change on fiscal 2024
−23.0%
Growth, 5 years
+3.6% a year
Growth, 10 years
+26.1% a year
Highest on record
$74.95Mfiscal 2019
Lowest on record
$5.25Mfiscal 2015
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Protagonist Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 3.6% a year; over ten years the rate was 26.1% a year. Across the 11 fiscal years on record (2015–2025), the highest was $74.95M in fiscal 2019 and the lowest $5.25M in fiscal 2015.

History · 11 fiscal years

Total liabilities by fiscal year

Protagonist Therapeutics total liabilities, year by year

Protagonist Therapeutics (PTGX) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$53.48M 23.0% down
2024$69.43M 226.4% up
2023$21.27M 34.2% down
2022$32.32M 32.2% down
2021$47.67M 6.3% up
2020$44.86M 40.1% down
2019$74.95M 178.0% up
2018$26.96M 37.5% down
2017$43.10M 569.8% up
2016$6.44M 22.6% up
2015$5.25M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Protagonist Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
Praxis Precision Medicines PRAX$59.77M2025
Twist Bioscience TWST$233.79M2026
Protagonist Therapeutics PTGX$53.48M2025
Krystal Biotech KRYS$114.23M2025
10x Genomics TXG$245.04M2025
HealthEquity HQY$1.27B2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics total liabilities: questions and answers

How large are Protagonist Therapeutics's total liabilities?

Protagonist Therapeutics (PTGX) had total liabilities of $53.48M at the end of fiscal 2025 (December 31, 2025). That is 23.0% lower than the $69.43M of fiscal 2024.

What is the growth rate of Protagonist Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 3.6% a year; over ten years the rate was 26.1% a year.

What are the highest and lowest total liabilities figures on record for Protagonist Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was $74.95M in fiscal 2019 and the lowest $5.25M in fiscal 2015.

How is Protagonist Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Protagonist Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/PTGX/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.